CJC-1295 no DAC 5 mg

CJC-1295 no DAC 5 mg — a stabilised GHRH analogue with a clean, short signalling window.
Also catalogued as modified GRF (1-29), CJC-1295 without DAC is the tetra-substituted GHRH fragment that laboratories reach for when they want GHRH-receptor activity without the extended half-life of the DAC-conjugated version. Supplied as a 5 mg lyophilised vial.

What is CJC-1295 no DAC?

CJC-1295 no DAC is a synthetic 29-amino-acid analogue derived from the biologically active N-terminal fragment of growth hormone-releasing hormone. Four amino acid substitutions are engineered into the native sequence to resist enzymatic cleavage — particularly at the dipeptidyl peptidase site that rapidly inactivates unmodified GHRH(1-29). Critically, the variant omits the drug affinity complex (DAC) moiety that binds serum albumin in the full CJC-1295 construct. The result is a peptide that retains GHRH-receptor agonism while producing a short, defined exposure profile, which is exactly what researchers want when studying pulsatile rather than sustained signalling.

Research interest

• GHRH receptor signalling — investigated in pituitary models examining receptor-mediated GH release.
• Pulsatility research — the short-acting profile makes it a preferred tool for studying episodic versus sustained stimulation.
• Peptide stabilisation chemistry — a worked example of substitution-based protease resistance in analogue design.
• Comparative secretagogue studies — used alongside GHS-R agonists to separate the two distinct GH-release pathways.
• DAC versus non-DAC comparison — of interest to researchers examining how albumin-binding conjugation alters peptide kinetics.

Specifications

• Content: 5 mg of active substance per vial
• Form: Lyophilised powder (sealed vial)
• Purity: Pharmaceutical-grade, batch-tested
• Storage: Sealed at 2–8 °C; −20 °C for extended storage, dry and shielded from light

Handling & storage

A 29-residue chain is considerably more conformationally fragile than a short hexapeptide, and handling should reflect that. Keep the vial sealed, cold and dry, and allow it to reach room temperature before opening to prevent moisture condensing onto the lyophilised cake. When reconstituting under your own validated protocol, run solvent slowly down the vial wall and let the cake dissolve passively — vortexing and vigorous shaking introduce shear forces that promote aggregation in longer Peptides. Reconstituted material should be held refrigerated, protected from light, and aliquoted in low-binding tubes for single use. Avoid repeated freeze–thaw cycling, and discard solutions showing cloudiness or visible particulates.

Why source from Rogue

• Verified purity — every batch is traceable, analytically tested and released against its own certificate.
• European supply chain — sealed, authentic vials, shipped from within the EU and never sourced grey-market.
• Discreet, tracked delivery — fast dispatch across Europe in protective packaging, tracked end to end.

For research purposes only. Not a medicinal product. Not for human or veterinary consumption. Intended for qualified laboratory research use only.

Related: HCG (Human Chorionic Gonadotropin) 5000 IU · NAD+ 1000 mg